Novo Holdings to acquire Ellab
Novo Holdings A/S, a leading global life sciences investor, today announced that it has agreed to acquire Ellab from EQT.
Headquartered in Hillerød, Denmark, Ellab (“Ellab”) provides validation and monitoring solutions and services for biotech and pharmaceutical processes. Its solutions and services measure and document parameters such as temperature, pressure and carbon dioxide, which helps clients to ensure consumer safety and regulatory compliance, while reducing time to market and the risk of product loss.
Initially established as a family-owned business in 1949 in Denmark, Ellab began its journey by developing temperature sensors for the food industry. Today, Ellab has transformed into a full-suite provider of validation and monitoring solutions and services for the biotech and pharmaceutical industries, serving a blue-chip customer base globally. Novo Holdings will support the continued growth of Ellab, building on the impressive long-standing track-record, by utilising its industry network and global presence to accelerate future business expansion.
